Anna Karlsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anna Karlsson has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Johan Staaf
Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden
4 shared publications - Göran Jönsson
Lund University
3 shared publications Johan Staaf
Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University, Lund, Sweden
3 shared publicationsMats Jönsson
Department of Clinical Sciences Lund, Division of Oncology, Lund University, Lund, Sweden
3 shared publications- Hans Brunnström
Division of Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
2 shared publications - Johan Vallon-Christersson
Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
2 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1) , 292
Integrated prediction of lung cancer histology and molecular profiles from small bronchoscopic tumor specimens
Treatment decisions in lung cancer rely on comprehensive molecular and histological characterization, but the limited amount of tumor tissue available from diagnostic procedures remains a major challenge. In this proof-of-concept study, we investigated whether preserving small bronchoscopic tumor specimens in RNAlater enables integrated molecular and histological profiling. Bronchial forceps biopsies and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) specimens were collected during the diagnostic work-up of patients with suspected lung cancer, preserved in RNAlater, and used for DNA, RNA, and protein extraction. RNA was analyzed using NanoString gene expression profiling and RNA-sequencing to assess treatment-relevant gene fusions, MET exon 14 skipping events, and histological subtypes. Somatic mutations were identified by massively parallel sequencing, and proteomics-based non-small cell lung cancer (NSCLC) subtypes were characterized by mass spectrometry. High-quality DNA, RNA, and proteins were successfully recovered from all tumors. Gene fusion analysis was successful in 44 of 45 cases. Gene expression-based histological classification showed good concordance with the clinical pathology diagnosis, although some discrepancies were observed. Mutation profiling was fully concordant with routine clinical testing, and comprehensive proteomic data were successfully generated. Collectively, these findings demonstrate that RNAlater-preserved bronchoscopic specimens provide material of sufficient quality for integrated multi-omics analyses, enabling comprehensive molecular profiling from a single, small tumor biopsy.
- 27 July 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1) , 292
Open AccessIntegrated prediction of lung cancer histology and molecular profiles from small bronchoscopic tumor specimens
Treatment decisions in lung cancer rely on comprehensive molecular and histological characterization, but the limited amount of tumor tissue available from diagnostic procedures remains a major challenge. In this proof-of-concept study, we investigated whether preserving small bronchoscopic tumor specimens in RNAlater enables integrated molecular and histological profiling. Bronchial forceps biopsies and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) specimens were collected during the diagnostic work-up of patients with suspected lung cancer, preserved in RNAlater, and used for DNA, RNA, and protein extraction. RNA was analyzed using NanoString gene expression profiling and RNA-sequencing to assess treatment-relevant gene fusions, MET exon 14 skipping events, and histological subtypes. Somatic mutations were identified by massively parallel sequencing, and proteomics-based non-small cell lung cancer (NSCLC) subtypes were characterized by mass spectrometry. High-quality DNA, RNA, and proteins were successfully recovered from all tumors. Gene fusion analysis was successful in 44 of 45 cases. Gene expression-based histological classification showed good concordance with the clinical pathology diagnosis, although some discrepancies were observed. Mutation profiling was fully concordant with routine clinical testing, and comprehensive proteomic data were successfully generated. Collectively, these findings demonstrate that RNAlater-preserved bronchoscopic specimens provide material of sufficient quality for integrated multi-omics analyses, enabling comprehensive molecular profiling from a single, small tumor biopsy.
- 9 March 2021
- Published by Springer Nature
- Vol. 2279, 91-107
Detection of Non-Small Lung Cell Carcinoma-Associated Genetic Alterations Using a NanoString Gene Expression Platform Approach
In non-small cell lung cancer (NSCLC), mutation detection and fusion gene status are treatment predictive and, hence, key factors in clinical management. Lately, alternate splicing variants of MET have gained focus as NSCLC tumors harboring a MET exon 14 skipping event have proven sensitive toward targeted therapy. Reliable methods for detection of genetic alterations in NSCLC have proven to be of increased importance. This chapter provides with hands-on experience of the NanoString gene expression platform for detection of genetic alterations in NSCLC.
- 9 March 2021
- Published by Springer Nature
- Vol. 2279, 91-107
Detection of Non-Small Lung Cell Carcinoma-Associated Genetic Alterations Using a NanoString Gene Expression Platform Approach
In non-small cell lung cancer (NSCLC), mutation detection and fusion gene status are treatment predictive and, hence, key factors in clinical management. Lately, alternate splicing variants of MET have gained focus as NSCLC tumors harboring a MET exon 14 skipping event have proven sensitive toward targeted therapy. Reliable methods for detection of genetic alterations in NSCLC have proven to be of increased importance. This chapter provides with hands-on experience of the NanoString gene expression platform for detection of genetic alterations in NSCLC.
- Open Access
Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer
Lung cancer is the worldwide leading cause of death from cancer. Epigenetic modifications such as methylation and changes in chromatin accessibility are major gene regulatory mechanisms involved in tumorigenesis and cellular lineage commitment. We aimed to characterize these processes in the context of neuroendocrine (NE) lung cancer. Illumina 450K DNA methylation data were collected for 1407 lung cancers including 27 NE tumors. NE differentially methylated regions (NE-DMRs) were identified and correlated with gene expression data for 151 lung cancers and 31 human tissue entities from the Genotype-Tissue Expression (GTEx) consortium. Assay for transposase-accessible chromatin sequencing (ATAC-seq) and RNA sequencing (RNA-seq) were performed on eight lung cancer cell lines, including three NE cell lines, to identify neuroendocrine specific gene regulatory elements. We identified DMRs with methylation patterns associated with differential gene expression and an NE tumor phenotype. DMR-associated genes could further be split into six functional modules, including one highly specific gene module for NE lung cancer showing high expression in both normal and malignant brain tissue. The regulatory potential of NE-DMRs was further validated in vitro using paired ATAC- and RNA-seq and revealed both proximal and distal regulatory elements of canonical NE-marker genes such as CHGA, NCAM1, INSM1, as well as a number of novel candidate markers of NE lung cancer. Using multilevel genomic analyses of both tumor bulk tissue and lung cancer cell lines, we identified a large catalogue of gene regulatory elements related to the NE phenotype of lung cancer.
Open AccessMethylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer
Lung cancer is the worldwide leading cause of death from cancer. Epigenetic modifications such as methylation and changes in chromatin accessibility are major gene regulatory mechanisms involved in tumorigenesis and cellular lineage commitment. We aimed to characterize these processes in the context of neuroendocrine (NE) lung cancer. Illumina 450K DNA methylation data were collected for 1407 lung cancers including 27 NE tumors. NE differentially methylated regions (NE-DMRs) were identified and correlated with gene expression data for 151 lung cancers and 31 human tissue entities from the Genotype-Tissue Expression (GTEx) consortium. Assay for transposase-accessible chromatin sequencing (ATAC-seq) and RNA sequencing (RNA-seq) were performed on eight lung cancer cell lines, including three NE cell lines, to identify neuroendocrine specific gene regulatory elements. We identified DMRs with methylation patterns associated with differential gene expression and an NE tumor phenotype. DMR-associated genes could further be split into six functional modules, including one highly specific gene module for NE lung cancer showing high expression in both normal and malignant brain tissue. The regulatory potential of NE-DMRs was further validated in vitro using paired ATAC- and RNA-seq and revealed both proximal and distal regulatory elements of canonical NE-marker genes such as CHGA, NCAM1, INSM1, as well as a number of novel candidate markers of NE lung cancer. Using multilevel genomic analyses of both tumor bulk tissue and lung cancer cell lines, we identified a large catalogue of gene regulatory elements related to the NE phenotype of lung cancer.
- Open Access
- 26 March 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 5207
A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer
Accurate histological classification and identification of fusion genes represent two cornerstones of clinical diagnostics in non-small cell lung cancer (NSCLC). Here, we present a NanoString gene expression platform and a novel platform-independent, single sample predictor (SSP) of NSCLC histology for combined, simultaneous, histological classification and fusion gene detection in minimal formalin fixed paraffin embedded (FFPE) tissue. The SSP was developed in 68 NSCLC tumors of adenocarcinoma (AC), squamous cell carcinoma (SqCC) and large-cell neuroendocrine carcinoma (LCNEC) histology, based on NanoString expression of 11 (CHGA, SYP, CD56, SFTPG, NAPSA, TTF-1, TP73L, KRT6A, KRT5, KRT40, KRT16) relevant genes for IHC-based NSCLC histology classification. The SSP was combined with a gene fusion detection module (analyzing ALK, RET, ROS1, MET, NRG1, and NTRK1) into a multicomponent NanoString assay. The histological SSP was validated in six cohorts varying in size (n = 11–199), tissue origin (early or advanced disease), histological composition (including undifferentiated cancer), and gene expression platform. Fusion gene detection revealed five EML4-ALK fusions, four KIF5B-RET fusions, two CD74-NRG1 fusion and three MET exon 14 skipping events among 131 tested cases. The histological SSP was successfully trained and tested in the development cohort (mean AUC = 0.96 in iterated test sets). The SSP proved successful in predicting histology of NSCLC tumors of well-defined subgroups and difficult undifferentiated morphology irrespective of gene expression data platform. Discrepancies between gene expression prediction and histologic diagnosis included cases with mixed histologies, true large cell carcinomas, or poorly differentiated adenocarcinomas with mucin expression. In summary, we present a proof-of-concept multicomponent assay for parallel histological classification and multiplexed fusion gene detection in archival tissue, including a novel platform-independent histological SSP classifier. The assay and SSP could serve as a promising complement in the routine evaluation of diagnostic lung cancer biopsies.
- 26 March 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 5207
Open AccessA combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer
Accurate histological classification and identification of fusion genes represent two cornerstones of clinical diagnostics in non-small cell lung cancer (NSCLC). Here, we present a NanoString gene expression platform and a novel platform-independent, single sample predictor (SSP) of NSCLC histology for combined, simultaneous, histological classification and fusion gene detection in minimal formalin fixed paraffin embedded (FFPE) tissue. The SSP was developed in 68 NSCLC tumors of adenocarcinoma (AC), squamous cell carcinoma (SqCC) and large-cell neuroendocrine carcinoma (LCNEC) histology, based on NanoString expression of 11 (CHGA, SYP, CD56, SFTPG, NAPSA, TTF-1, TP73L, KRT6A, KRT5, KRT40, KRT16) relevant genes for IHC-based NSCLC histology classification. The SSP was combined with a gene fusion detection module (analyzing ALK, RET, ROS1, MET, NRG1, and NTRK1) into a multicomponent NanoString assay. The histological SSP was validated in six cohorts varying in size (n = 11–199), tissue origin (early or advanced disease), histological composition (including undifferentiated cancer), and gene expression platform. Fusion gene detection revealed five EML4-ALK fusions, four KIF5B-RET fusions, two CD74-NRG1 fusion and three MET exon 14 skipping events among 131 tested cases. The histological SSP was successfully trained and tested in the development cohort (mean AUC = 0.96 in iterated test sets). The SSP proved successful in predicting histology of NSCLC tumors of well-defined subgroups and difficult undifferentiated morphology irrespective of gene expression data platform. Discrepancies between gene expression prediction and histologic diagnosis included cases with mixed histologies, true large cell carcinomas, or poorly differentiated adenocarcinomas with mucin expression. In summary, we present a proof-of-concept multicomponent assay for parallel histological classification and multiplexed fusion gene detection in archival tissue, including a novel platform-independent histological SSP classifier. The assay and SSP could serve as a promising complement in the routine evaluation of diagnostic lung cancer biopsies.
- 17 January 2019
- Published by Springer Nature
- Vol. 1908, 139-152
Clinical Application of Fusion Gene Detection Using Next-Generation Sequencing and the NanoString Technology
Fusion gene detection is of great diagnostic value since the presence of fusion genes may dictate treatment and patient outcome. When detecting fusion genes in clinical samples there are multiple aspects to consider regarding sample origin, choice of fusion gene detection technique, and data analysis.
- 17 January 2019
- Published by Springer Nature
- Vol. 1908, 139-152
Clinical Application of Fusion Gene Detection Using Next-Generation Sequencing and the NanoString Technology
Fusion gene detection is of great diagnostic value since the presence of fusion genes may dictate treatment and patient outcome. When detecting fusion genes in clinical samples there are multiple aspects to consider regarding sample origin, choice of fusion gene detection technique, and data analysis.
- Open Access
- 6 November 2015
- Published by Springer Nature in BMC Medical Genomics
- Vol. 8 (1) , 73
DNA methylation subgroups in melanoma are associated with proliferative and immunological processes
DNA methylation at CpG dinucleotides is modified in tumorigenesis with potential impact on transcriptional activity. We used the Illumina 450 K platform to evaluate DNA methylation patterns of 50 metastatic melanoma tumors, with matched gene expression data. We identified three different methylation groups and validated the groups in independent data from The Cancer Genome Atlas. One group displayed hypermethylation of a developmental promoter set, genome-wide demethylation, increased proliferation and activity of the SWI/SNF complex. A second group had a methylation pattern resembling stromal and leukocyte cells, over-expressed an immune signature and had improved survival rates in metastatic tumors (p < 0.05). A third group had intermediate methylation levels and expressed both proliferative and immune signatures. The methylation groups corresponded to some degree with previously identified gene expression phenotypes. Melanoma consists of divergent methylation groups that are distinguished by promoter methylation, proliferation and content of immunological cells.
- 6 November 2015
- Published by Springer Nature in BMC Medical Genomics
- Vol. 8 (1) , 73
Open AccessDNA methylation subgroups in melanoma are associated with proliferative and immunological processes
DNA methylation at CpG dinucleotides is modified in tumorigenesis with potential impact on transcriptional activity. We used the Illumina 450 K platform to evaluate DNA methylation patterns of 50 metastatic melanoma tumors, with matched gene expression data. We identified three different methylation groups and validated the groups in independent data from The Cancer Genome Atlas. One group displayed hypermethylation of a developmental promoter set, genome-wide demethylation, increased proliferation and activity of the SWI/SNF complex. A second group had a methylation pattern resembling stromal and leukocyte cells, over-expressed an immune signature and had improved survival rates in metastatic tumors (p < 0.05). A third group had intermediate methylation levels and expressed both proliferative and immune signatures. The methylation groups corresponded to some degree with previously identified gene expression phenotypes. Melanoma consists of divergent methylation groups that are distinguished by promoter methylation, proliferation and content of immunological cells.
- Open Access
- 2 February 2015
- Published by Springer Nature in Genome Medicine
- Vol. 7 (1) , 1-12
The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine
Background: Breast cancer exhibits significant molecular, pathological, and clinical heterogeneity. Current clinicopathological evaluation is imperfect for predicting outcome, which results in overtreatment for many patients, and for others, leads to death from recurrent disease. Therefore, additional criteria are needed to better personalize care and maximize treatment effectiveness and survival. Methods: To address these challenges, the Sweden Cancerome Analysis Network - Breast (SCAN-B) consortium was initiated in 2010 as a multicenter prospective study with longsighted aims to analyze breast cancers with next-generation genomic technologies for translational research in a population-based manner and integrated with healthcare; decipher fundamental tumor biology from these analyses; utilize genomic data to develop and validate new clinically-actionable biomarker assays; and establish real-time clinical implementation of molecular diagnostic, prognostic, and predictive tests. In the first phase, we focus on molecular profiling by next-generation RNA-sequencing on the Illumina platform. Results: In the first 3 years from 30 August 2010 through 31 August 2013, we have consented and enrolled 3,979 patients with primary breast cancer at the seven hospital sites in South Sweden, representing approximately 85% of eligible patients in the catchment area. Preoperative blood samples have been collected for 3,942 (99%) patients and primary tumor specimens collected for 2,929 (74%) patients. Herein we describe the study infrastructure and protocols and present initial proof of concept results from prospective RNA sequencing including tumor molecular subtyping and detection of driver gene mutations. Prospective patient enrollment is ongoing. Conclusions: We demonstrate that large-scale population-based collection and RNA-sequencing analysis of breast cancer is feasible. The SCAN-B Initiative should significantly reduce the time to discovery, validation, and clinical implementation of novel molecular diagnostic and predictive tests. We welcome the participation of additional comprehensive cancer treatment centers. Trial registration: ClinicalTrials.gov identifier NCT02306096.
- 2 February 2015
- Published by Springer Nature in Genome Medicine
- Vol. 7 (1) , 1-12
Open AccessThe Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine
Background: Breast cancer exhibits significant molecular, pathological, and clinical heterogeneity. Current clinicopathological evaluation is imperfect for predicting outcome, which results in overtreatment for many patients, and for others, leads to death from recurrent disease. Therefore, additional criteria are needed to better personalize care and maximize treatment effectiveness and survival. Methods: To address these challenges, the Sweden Cancerome Analysis Network - Breast (SCAN-B) consortium was initiated in 2010 as a multicenter prospective study with longsighted aims to analyze breast cancers with next-generation genomic technologies for translational research in a population-based manner and integrated with healthcare; decipher fundamental tumor biology from these analyses; utilize genomic data to develop and validate new clinically-actionable biomarker assays; and establish real-time clinical implementation of molecular diagnostic, prognostic, and predictive tests. In the first phase, we focus on molecular profiling by next-generation RNA-sequencing on the Illumina platform. Results: In the first 3 years from 30 August 2010 through 31 August 2013, we have consented and enrolled 3,979 patients with primary breast cancer at the seven hospital sites in South Sweden, representing approximately 85% of eligible patients in the catchment area. Preoperative blood samples have been collected for 3,942 (99%) patients and primary tumor specimens collected for 2,929 (74%) patients. Herein we describe the study infrastructure and protocols and present initial proof of concept results from prospective RNA sequencing including tumor molecular subtyping and detection of driver gene mutations. Prospective patient enrollment is ongoing. Conclusions: We demonstrate that large-scale population-based collection and RNA-sequencing analysis of breast cancer is feasible. The SCAN-B Initiative should significantly reduce the time to discovery, validation, and clinical implementation of novel molecular diagnostic and predictive tests. We welcome the participation of additional comprehensive cancer treatment centers. Trial registration: ClinicalTrials.gov identifier NCT02306096.
- Open Access
- 7 June 2012
- Published by Springer Nature in BMC Medical Genomics
- Vol. 5 (1) , 22
Relation between smoking history and gene expression profiles in lung adenocarcinomas
Background: Lung cancer is the worldwide leading cause of death from cancer. Tobacco usage is the major pathogenic factor, but all lung cancers are not attributable to smoking. Specifically, lung cancer in never-smokers has been suggested to represent a distinct disease entity compared to lung cancer arising in smokers due to differences in etiology, natural history and response to specific treatment regimes. However, the genetic aberrations that differ between smokers and never-smokers’ lung carcinomas remain to a large extent unclear. Methods: Unsupervised gene expression analysis of 39 primary lung adenocarcinomas was performed using Illumina HT-12 microarrays. Results from unsupervised analysis were validated in six external adenocarcinoma data sets (n=687), and six data sets comprising normal airway epithelial or normal lung tissue specimens (n=467). Supervised gene expression analysis between smokers and never-smokers were performed in seven adenocarcinoma data sets, and results validated in the six normal data sets. Results: Initial unsupervised analysis of 39 adenocarcinomas identified two subgroups of which one harbored all never-smokers. A generated gene expression signature could subsequently identify never-smokers with 79-100% sensitivity in external adenocarcinoma data sets and with 76-88% sensitivity in the normal materials. A notable fraction of current/former smokers were grouped with never-smokers. Intriguingly, supervised analysis of never-smokers versus smokers in seven adenocarcinoma data sets generated similar results. Overlap in classification between the two approaches was high, indicating that both approaches identify a common set of samples from current/former smokers as potential never-smokers. The gene signature from unsupervised analysis included several genes implicated in lung tumorigenesis, immune-response associated pathways, genes previously associated with smoking, as well as marker genes for alveolar type II pneumocytes, while the best classifier from supervised analysis comprised genes strongly associated with proliferation, but also genes previously associated with smoking. Conclusions: Based on gene expression profiling, we demonstrate that never-smokers can be identified with high sensitivity in both tumor material and normal airway epithelial specimens. Our results indicate that tumors arising in never-smokers, together with a subset of tumors from smokers, represent a distinct entity of lung adenocarcinomas. Taken together, these analyses provide further insight into the transcriptional patterns occurring in lung adenocarcinoma stratified by smoking history.
- 7 June 2012
- Published by Springer Nature in BMC Medical Genomics
- Vol. 5 (1) , 22
Open AccessRelation between smoking history and gene expression profiles in lung adenocarcinomas
Background: Lung cancer is the worldwide leading cause of death from cancer. Tobacco usage is the major pathogenic factor, but all lung cancers are not attributable to smoking. Specifically, lung cancer in never-smokers has been suggested to represent a distinct disease entity compared to lung cancer arising in smokers due to differences in etiology, natural history and response to specific treatment regimes. However, the genetic aberrations that differ between smokers and never-smokers’ lung carcinomas remain to a large extent unclear. Methods: Unsupervised gene expression analysis of 39 primary lung adenocarcinomas was performed using Illumina HT-12 microarrays. Results from unsupervised analysis were validated in six external adenocarcinoma data sets (n=687), and six data sets comprising normal airway epithelial or normal lung tissue specimens (n=467). Supervised gene expression analysis between smokers and never-smokers were performed in seven adenocarcinoma data sets, and results validated in the six normal data sets. Results: Initial unsupervised analysis of 39 adenocarcinomas identified two subgroups of which one harbored all never-smokers. A generated gene expression signature could subsequently identify never-smokers with 79-100% sensitivity in external adenocarcinoma data sets and with 76-88% sensitivity in the normal materials. A notable fraction of current/former smokers were grouped with never-smokers. Intriguingly, supervised analysis of never-smokers versus smokers in seven adenocarcinoma data sets generated similar results. Overlap in classification between the two approaches was high, indicating that both approaches identify a common set of samples from current/former smokers as potential never-smokers. The gene signature from unsupervised analysis included several genes implicated in lung tumorigenesis, immune-response associated pathways, genes previously associated with smoking, as well as marker genes for alveolar type II pneumocytes, while the best classifier from supervised analysis comprised genes strongly associated with proliferation, but also genes previously associated with smoking. Conclusions: Based on gene expression profiling, we demonstrate that never-smokers can be identified with high sensitivity in both tumor material and normal airway epithelial specimens. Our results indicate that tumors arising in never-smokers, together with a subset of tumors from smokers, represent a distinct entity of lung adenocarcinomas. Taken together, these analyses provide further insight into the transcriptional patterns occurring in lung adenocarcinoma stratified by smoking history.
- Open Access
- 11 April 2008
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 98
Prognostic Impact of Array-based Genomic Profiles in Esophageal Squamous Cell Cancer
Esophageal squamous cell carcinoma (ESCC) is a genetically complex tumor type and a major cause of cancer related mortality. Although distinct genetic alterations have been linked to ESCC development and prognosis, the genetic alterations have not gained clinical applicability. We applied array-based comparative genomic hybridization (aCGH) to obtain a whole genome copy number profile relevant for identifying deranged pathways and clinically applicable markers.
- 11 April 2008
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 98
Open AccessPrognostic Impact of Array-based Genomic Profiles in Esophageal Squamous Cell Cancer
Esophageal squamous cell carcinoma (ESCC) is a genetically complex tumor type and a major cause of cancer related mortality. Although distinct genetic alterations have been linked to ESCC development and prognosis, the genetic alterations have not gained clinical applicability. We applied array-based comparative genomic hybridization (aCGH) to obtain a whole genome copy number profile relevant for identifying deranged pathways and clinically applicable markers.